Based on the Verona Pharma PLC ADR stock forecast from 6 analysts, the average analyst target price for Verona Pharma PLC ADR is USD 40.27 over the next 12 months. Verona Pharma PLC ADR’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Verona Pharma PLC ADR is Slightly Bearish, which is based on 3 positive signals and 5 negative signals. At the last closing, Verona Pharma PLC ADR’s stock price was USD 42.02. Verona Pharma PLC ADR’s stock price has changed by +1.45% over the past week, +8.27% over the past month and +139.29% over the last year.
No recent analyst target price found for Verona Pharma PLC ADR
No recent average analyst rating found for Verona Pharma PLC ADR
Company Overview Verona Pharma PLC ADR
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom. Read Less
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosp...Read More
Frequently Asked Questions About Verona Pharma PLC ADR (VRNA) Stock
Based on ratings from 6 analysts Verona Pharma PLC ADR's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 11 buy, sell and hold ratings.
Unfortunately we do not have enough data on VRNA's stock to indicate if its a good dividend stock.
Based on targets from 6 analysts, the average taret price for VRNA is USD 40.27 over the next 12 months. The maximum analyst target price is USD 50 while the minimum anlayst target price is USD 35.
Unfortunately we do not have enough data on VRNA's stock to indicate if its overvalued.
The last closing price of VRNA's stock was USD 42.02.
The most recent market capitalization for VRNA is USD 3.39B.
Based on targets from 6 analysts, the average taret price for VRNA is projected at USD 40.27 over the next 12 months.
This means that VRNA's stock price may go down by -4.16% over the next 12 months.
We can't find any ETFs which contains Verona Pharma PLC ADR's stock.
As per our most recent records Verona Pharma PLC ADR has 79 Employees.
Verona Pharma PLC ADR's registered address is 3 More London Riverside, London, United Kingdom, SE1 2RE.
You can get more information about it from Verona Pharma PLC ADR's website at https://www.veronapharma.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Frequently Asked Questions About Verona Pharma PLC ADR (VRNA) Stock
Based on ratings from 6 analysts Verona Pharma PLC ADR's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 11 buy, sell and hold ratings.
Unfortunately we do not have enough data on VRNA's stock to indicate if its a good dividend stock.
Based on targets from 6 analysts, the average taret price for VRNA is USD 40.27 over the next 12 months. The maximum analyst target price is USD 50 while the minimum anlayst target price is USD 35.
Unfortunately we do not have enough data on VRNA's stock to indicate if its overvalued.
The last closing price of VRNA's stock was USD 42.02.
The most recent market capitalization for VRNA is USD 3.39B.
Based on targets from 6 analysts, the average taret price for VRNA is projected at USD 40.27 over the next 12 months.
This means that VRNA's stock price may go down by -4.16% over the next 12 months.
We can't find any ETFs which contains Verona Pharma PLC ADR's stock.
As per our most recent records Verona Pharma PLC ADR has 79 Employees.
Verona Pharma PLC ADR's registered address is 3 More London Riverside, London, United Kingdom, SE1 2RE.
You can get more information about it from Verona Pharma PLC ADR's website at https://www.veronapharma.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for VRNA !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
